5 SIMPLE STATEMENTS ABOUT ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS EXPLAINED

In Segment A, participants will acquire unique doses and schedules of oral ABBV-744 pill to establish Safe and sound dosing routine. Extra contributors are going to be enrolled for the recognized monotherapy dosign program. In Segment B, members will receive oral ruxolitinib and ABBV-744 will be given as "insert-on" therapy. In Segment C, contribut